A Phase 1 Study of IRX195183, a RARα-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML

Subsets of non-acute promyelocytic leukemia (APL) acute myelogenous leukemia (AML) exhibit aberrant retinoid signaling and demonstrate sensitivity to retinoids in vitro. We present the results of a phase 1 dose-escalation study that evaluated the safety, pharmacodynamics, and efficacy of IRX195183,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ambinder, Alexander J., Norsworthy, Kelly, Hernandez, Daniela, Palau, Laura, Paun, Bogdan, Duffield, Amy, Chandraratna, Rosh, Sanders, Martin, Varadhan, Ravi, Jones, Richard J., Douglas Smith, B., Ghiaur, Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7645224/
https://www.ncbi.nlm.nih.gov/pubmed/33194741
http://dx.doi.org/10.3389/fonc.2020.587062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7645224/
https://www.ncbi.nlm.nih.gov/pubmed/33194741
http://dx.doi.org/10.3389/fonc.2020.587062

Ejemplares similares